PREVALENCE AND ASSOCIATED FACTORS OF SARCOPENIA IN LUNG CANCER PATIENTS UNDERGOING CHEMOTHERAPY: A CROSS-SECTIONAL STUDY AT A TERTIARY HOSPITAL IN VIETNAM

Pham Duc Minh1, , Bui Do Quynh Huong1
1 Department of Nutrition, Military Hospital 103, Vietnam Medical Military University

Nội dung chính của bài viết

Tóm tắt

Objectives: To evaluate the prevalence of sarcopenia and its associated factors in lung cancer patients undergoing chemotherapy at a tertiary hospital in Vietnam. Methods: A cross-sectional descriptive study was conducted on 89 lung cancer patients. Sarcopenia was assessed using the Asian Working Group for Sarcopenia (AWGS) 2019 criteria, including measurements of handgrip strength (HGS), appendicular skeletal muscle mass (ASM), and physical performance. Logistic regression analysis identified factors associated with sarcopenia. Results: The mean age of participants was 62.6 ± 9.8 years; 78.7% were male. The prevalence of sarcopenia was 39.3%, with 40.4% of patients having reduced ASM. Malnutrition (Body mass index (BMI) < 18.5) was found in 15.7% of patients. Logistic regression analysis revealed significant associations between sarcopenia and male gender (OR = 8.19), lower hemoglobin levels (OR = 0.96), and increased lymphocyte counts (OR = 1.05). Patients with normal BMI (18.5 - 23) and high BMI (≥ 23) had lower odds of sarcopenia compared to those with BMI < 18.5. Conclusion: Sarcopenia is prevalent among lung cancer patients undergoing chemotherapy. Male gender, low BMI, low HGB, and high lymphocyte counts are associated with increased sarcopenia risk in lung cancer patients, whereas normal to high BMI offers protective effects.

Chi tiết bài viết

Tài liệu tham khảo

1. Chen LK, J Woo, P Assantachai, et al. Asian working group for sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment. J Am Med Dir Assoc. 2020; 21(3):300-307.e2.
2. Anjanappa M, M Corden, A Green, et al. Sarcopenia in cancer: Risking more than muscle loss. Tech Innov Patient Support Radiat Oncol. 2020; 16:50-57.
3. Au PC, HL Li, GK Lee, et al. Sarcopenia and mortality in cancer: A meta-analysis. Osteoporos Sarcopenia. 2021; 7(Suppl 1):S28-S33.
4. Sun Q, X Jiang, R Qin, et al. Sarcopenia among older patients with cancer: A scoping review of the literature. J Geriatr Oncol. 2022; 13(7):924-934.
5. Globocan. Global Cancer. 2020.
6. Jensen S, Z Bloch, M Quist, et al. Sarcopenia and loss of muscle mass in patients with lung cancer undergoing chemotherapy treatment: A systematic review and meta-analysis. Acta Oncol. 2023; 62(3):318-328.
7. Nguyễn DĐ, ĐM Phạm, VS Nguyễn. Tần suất sarcopenia ở bệnh nhân bệnh tim thiếu máu cục bộ mạn tính. Tạp chí Y học Việt Nam. 2023; 531(1).
8. Hoang DK, MC Doan, NM Le, et al. Prevalence of and risk factors for sarcopenia in community-dwelling people: The Vietnam osteoporosis study. J Cachexia Sarcopenia Muscle. 2024; 15(1):380-386.
9. Surov A and A Wienke. Prevalence of sarcopenia in patients with solid tumors: A meta-analysis based on 81,814 patients. JPEN J Parenter Enteral Nutr. 2022; 46(8):1761-1768.
10. Kiss N. Nutrition support and dietary interventions for patients with lung cancer: Current insights. Lung Cancer (Auckl). 2016; 7:1-9.